Circulating miR-134 in Mesial Temporal Lobe Epilepsy
Author Information
Author(s): Bárbara Guerra Leal, Cláudia Carvalho, Cristina Santos, Raquel Samões, Ricardo Martins-Ferreira, Catarina Teixeira, Diana Rodrigues, Joel Freitas, Carolina Lemos, Rui Chorão, João Ramalheira, João Lopes, António Martins da Silva, Paulo Pinho e Costa, João Chaves
Primary Institution: UMIB-Unit for Multidisciplinary Research in Biomedicine, ICBAS- Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Porto, Portugal
Hypothesis
This study aims to quantify serum levels of miR-134 in patients with Mesial Temporal Lobe Epilepsy-Hippocampal Sclerosis and Genetic Generalized Epilepsies, and explore its correlation with clinical parameters.
Conclusion
miR-134 circulating levels are associated with drug-resistant epilepsy, particularly in patients with hippocampal sclerosis.
Supporting Evidence
- Patients with elevated miR-134 levels were at higher risk of drug-resistant epilepsy.
- Hippocampal sclerosis was the strongest predictor of drug-resistant epilepsy.
- Circulating miR-134 levels were significantly higher in MTLE-HS patients compared to controls.
Takeaway
This study found that a molecule called miR-134 is higher in people with a type of epilepsy that doesn't respond to medicine, which might help doctors find new treatments.
Methodology
Serum levels of miR-134 were evaluated in 131 epilepsy patients and 42 healthy individuals using quantitative RT-PCR.
Limitations
The study lacks validation cohorts and does not account for the effects of antiepileptic medications on miR-134 levels.
Participant Demographics
The study included 131 patients (75 women, 56 men; mean age 41.10 years) and 42 healthy individuals (25 women, 17 men; mean age 42.40 years).
Statistical Information
P-Value
p=0.021
Confidence Interval
95% CI 0.551–0.751
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website